Repurposed quinacrine synergizes with cisplatin, reducing the effective dose required for treatment of head and neck squamous cell carcinoma

Despite highly toxic treatments, head and neck squamous cell carcinoma (HNSCC) have poor outcomes. There is an unmet need for more effective, less toxic therapies. Repurposing of clinically-approved drugs, with known safety profiles, may provide a time- and cost-effective approach to address this ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Bryant, Jennifer, Batis, Nikolaos, Franke, Anna Clara, Clancey, Gabriella, Hartley, Margaret, Ryan, Gordon, Brooks, Jill, Southam, Andrew D., Barnes, Nicholas, Parish, Joanna, Roberts, Sally, Khanim, Farhat, Spruce, Rachel, Mehanna, Hisham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718257/
https://www.ncbi.nlm.nih.gov/pubmed/31497252
http://dx.doi.org/10.18632/oncotarget.27156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718257/
https://www.ncbi.nlm.nih.gov/pubmed/31497252
http://dx.doi.org/10.18632/oncotarget.27156

Ejemplares similares